Supplemental l-arginine during cardioplegic arrest and reperfusion avoids regional postischemic injury  by Sato, Hiroki et al.
SUPPLEMENTAL L-ARGININE 
DURING CARDIOPLEGIC 
ARREST AND REPERFUSION 
AVOIDS REGIONAL 
POSTISCHEMIC INJURY 
Unenhanced hypothermic cardioplegia does not prevent postischemic endo- 
thelial and contractile dysfunction in hearts subjected to antecedent regional 
or global ischemia. This study tested the hypothesis that supplementing blood 
cardioplegic solution a d reperfusion with the nitric oxide precursor L- 
arginine would preserve ndothelial function, reduce infarct size, and reverse 
postcardioplegia regional contractile dysfunction by the L-arginine-nitric oxide 
pathway. In 23 anesthetized dogs, the left anterior descending coronary artery 
was iigated for 90 minutes, after which total bypass was established for surgical 
"revascularization." In 10 dogs, unsupplemented muitidose hypothermic blood 
cardioplegic solution was administered for a total of 60 minutes of cardioplegic 
arrest. In eight dogs, L-arginine was given intravenously (4mg/kg per minute) 
and in blood cardioplegic solution (10 mmol) during arrest. In five dogs, the 
nitric oxide synthesis blocker Nco-nitro-L-arginine (1 mmol) was used to block 
the L-arginine-nitric oxide pathway during cardioplegia nd reperfusion. 
Infarct size (triphenyltetrazolium chloride) as percent of the area at risk was 
significantly reduced by L-arginine compared with blood cardioplegic solution 
(28.2% - 4.1% versus 40.5% -+ 3.5%) and was reversed by Nm-nitro-L-arginine 
to 68.9% +- 3.0% (p < 0.05). Postischemic regional segmental work in 
millimeters of mercury per millimeter (sonomicrometry) was significantly 
better with L-arginine (92 + 15) versus blood cardioplegic solution (28 +- 3) 
and Nco-nitro-L-arginine (26 -- 6). Segmental diastolic stiffness was signifi- 
cantly lower with L-arginine (0.46 -- 0.06) compared with blood cardioplegic 
solution (1.10 - 0.11) and was significantly greater with NoJ-nitro-L-arginine 
(2.70 -- 0.43). In ischemic-reperfused l ft anterior descending coronary 
arterial vascular rings, maximum relaxation responses to acetylcholine, the 
stimulator of endothelial nitric oxide, was depressed in the blood cardioplegic 
solution group (77% - 4%) and was significantly reversed by L-arginine (92% 
-- 3%). Smooth muscle function was unaffected in all groups. We conclude 
that cardioplegic solution supplemented with L-arginine reduces infarct 
size, preserves postischemic systolic and diastolic regional function, and 
prevents arterial endothelial dysfunction via the L-arginine-nitric oxide 
pathway. (J THORAC CARDIOVASC SURG 1995;110:302-14) 
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p rolonged regional ischemia produces myocardial 
necrosis within 1 hour of occlusion despite reper- 
fusion. 1 In addition, previous studies have demon- 
strated that both regional and global myocardial 
ischemia and reperfusion injure the coronary artery 
endothelium, manifested as impaired coronary vas- 
cular responses to various endothelium-dependent 
vasodilators. 1-6 This endothelial dysfunction may be 
physiologically expressed as a reduced production or 
release of endothelium-derived relaxing factor. En- 
dothelium-derived relaxing factor is synonymous 
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with nitric oxide (NO) itself or a nitroso intermedi- 
ate compound 7 and acts not only as an endogenous 
nitrovasodilator s but also as an inhibitor of platelet 
aggregation, 9 an antineutrophil autacoid reducing 
adherence to the vascular endothelium, 1 and a 
direct diradical coupling agent of superoxide an- 
ions. l° Because the antineutrophil and antioxidant 
activities of NO released by the coronary endothe- 
lium are important cardioprotective mechanisms 
that prevent injury to the endothelium and myo- 
cytes, the loss of this endogenous cardioprotection 
subsequent to endothelial damage may be an impor- 
tant component in the pathophysiologic progression 
of myocardial ischemia-reperfusion njury. 
Protecting the myocardium during cardiac opera- 
tions with hypothermic ardioplegic solutions has 
been widely used to both prevent ischemic injury 
during elective cardiac arrest and reduce injury after 
subsequent reperfusion. In clinical cardiac opera- 
tions, the heart is exposed not only to protected 
ischemia, but also to antecedent unprotected isch- 
emia (coronary artery occlusion, oxygen supply/ 
demand mismatch) and reperfusion during infusion 
of cardioplegic solution or removal of the aortic 
crossclamp. The potential for injury exists at each of 
these points. The cardioplegic solution would be an 
ideal vehicle, for the delivery of agents that target he 
perpetrators; of endothelial and myocyte injury dur- 
ing elective cardiac arrest and subsequent reperfu- 
sion. Replacement of NO by an exogenous NO 
donor or, alternatively, supplementation with a pre- 
cursor of NO (that is, L-arginine) ll may prevent 
endothelial damage, reduce necrosis, and preserve 
postischemic function after regional ischemia. 
This study tested the hypothesis that adjuvant 
L-arginine, the precursor of NO, administered dur- 
ing hypothermic cardioplegic arrest and reperfusion 
would attenuate ndothelial dysfunction, reduce in- 
farct size, and reverse postcardioplegia regional 
dysfunction by the L-arginine-NO pathway in dogs 
subjected to 1.5 hours of collateral-deficient re- 
gional ischemia, 1 multidose blood cardioplegia, and 
reperfusion. 
Material and methods 
The dogs were handled in compliance with the "Guide 
for the Care and Use of Laboratory Animals" published 
by the National Institutes of Health (NIH Publication No. 
85-23, revised 1985). The institutional Animal Care and 
Use Committee approved the study protocol. 
Surgical procedure. Heartworm-free adult mongrel 
dogs weighing 19.0 to 35.7 kg (average 23.2 kg) of either 
sex were initially anesthetized with intravenous sodium 
thiamylal (20 mg/kg). A bolus injection of fentanyl citrate 
(350 /xg) and diazepam (5 rag) was given followed by 
continuous infusion of fentanyl citrate (0.3 /xg/kg per 
minute) and diazepam (0.03 mg/kg per minute) during the 
experiment. Each dog was endotracheally intubated and 
the lungs were ventilated with oxygen-enriched room air 
to maintain arterial oxygen tension greater than 100 mm 
Hg with use of a volume-cycled respirator (Harvard 
Apparatus, South Natick, Mass.). The right femoral artery 
and vein were cannulated for arterial blood sampling and 
for fluid administration, respectively. Arterial carbon di- 
oxide tension was maintained between 35 and 45 mm Hg 
by adjustment of ventilatory rate, and pH was adjusted 
between 7.37 and 7.43 with intravenous sodium bicarbon- 
ate as necessary. 
The surgical preparation used in the present study for 
assessing regional segmental function by sonomicrometry 3 
and creating collateral-deficient regional ischemia 1 has 
been presented indetail elsewhere. After dissection of the 
proximal portion of the left anterior descending (LAD) 
coronary artery, a small right ventricular branch of the 
LAD distal to the point of ligation was dissected free for 
arteriotomy and retrograde venting of collateral blood 
flow to minimize collateral perfusion during LAD occlu- 
sionJ The dogs were systemically heparinized with hepa- 
rin sodium 300 U/kg, supplemented at 300 U/kg every 90 
minutes. The left subclavian artery was cannulated for 
aortic perfusion. Superior and inferior vena caval cannu- 
las were inserted transatrially into the right atrium and 
poised in the atrium so not to impair venous return. 
Hemodynamic and segmental function data were ob- 
tained at baseline with the circulation intact. Each dog 
then received a bolus injection of lidocaine (1.2 mg/kg), 
after which the LAD and obvious collateral vessels en- 
croaching on the territory perfused by the LAD were 
ligated for 90 minutes of regional ischemia. Immediately 
after LAD ligation, a small right ventricular branch of the 
LAD was transected to divert collateral blood flow from 
the ischemic zone. This technique has been shown to 
result in the uniform depletion of collateral flow to all 
layers of the canine myocardium and has been shown to 
produce aconsistent degree of necrosis within the area at 
risk. l Ventricular fibrillation, when encountered, was con- 
verted by direct-current countershocks of 15 watt-seconds. 
After 90 minutes of regional ischemia, hemodynamic and 
segmental function data were collected again. Cardiopul- 
monary bypass was instituted as previously described. 12
Experimental protocol. Dogs were randomly divided 
into three groups on the basis of the exclusion or inclusion 
of the NO-precursor L-arginine (L-Arg group) or the NO 
synthesis blocker N~o-nitro-L-arginine (L-NA; L-NA 
group) in blood cardioplegia and as intravenous supple- 
ment. In the BCP group (BCP group, n = 10), unmodified 
standard blood cardioplegia 5 was used. In the L-Arg group 
(n = 8), L-arginine was added to blood cardioplegia to 
achieve a final concentration i  the blood cardioplegic 
solution of 10 mmol/L 3and administered intravenously (4 
mg/kg per minute infusion rate) from the application of 
the aortic crossclamp to the end of the experiment. In the 
third group (L-NA, n = 5) L-NA was added to blood 
cardioplegia (1retool/L) and infused systemically by bolus 
intravenous injection (16.8 mg/kg body weight) just before 
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Table I. Hemodynamic data at baseline, ischemia, 
and reperfusion 
90 Minutes 
Baseline of ischemia Reperfusion 
HR (beats/min) 
BCP 104 + 7 124 _+ 6* 149 _+ 4* 
L-Arg 91 + 9 131 _+ 7* 139 + 6* 
L-NA 105 ± 8 127 _+ 5* 131 + 4*t 
MAP (ram Hg) 
BCP 105 ,+ 2 85 + 3* 82 _+ 2 
L-Arg 97 ,+ 4 92 -+ 2* 87 + 2 
L-NA 94 ,+ 4"~ 87 ± 1" 85 ± 2* 
PRP (ram Hg/ 
min x 103) 
BCP 12.0 ,+ 0.8 11.0 -- 0.7* 14.2 ± 0.5* 
L-Arg 9.8 ,+ 1.2 12.7 -+ 0.8* 14.7 ± 0.9* 
L-NA 10.2 + 0.5 11.6 -+ 0.6* 12.9 ± 0.7* 
Values are given as means plus or minus the standard error of the estimate. 
HR, Heart rate; MAP, mean arterial pressure; PRP, pressure-rate product. 
*p < 0.05 versus previous period. 
"~p < 0.05 versus BCP group. 
infusion of L-arginine (10 mmol/L) and each hour there- 
after. Preliminary experiments showed that a 1 mmol/L 
concentration of L-NA blocked the endogenous NO re- 
lease stimulated by acetylcholine for the duration of the 
experiment. 
Cardioplegic arrest. After the aorta was crossclamped, 
blood cardioptegic solution was delivered by the warm- 
cold induction modality 13 and terminal warm infusion. 
Potassium level was 20 to 25 mmol/L during warm infu- 
sions and 10 mmol/L during cold infusions. Calcium level 
was 0.2 to 0.3 mmol/L, pH 7 to 9 at 37 ° C, and osmolality 
360 to 380/xOsm. Hematocrit value ranged from 0.14 to 
0.18. The LAD vessel oop was removed and the site of 
coronary artery collateral venting closed before the 20- 
minute administration of supplemental cardioplegia, 
which thereby allowed delivery of blood cardioplegic 
solution down the LAD. Systemic temperature was main- 
tained at 28 ° C. After the final infusion of blood cardiople- 
gic solution, systemic rewarming to 37 ° C was completed, 
and the crossclamp was removed immediately after com- 
pletion of the terminal blood cardioplegic nfusion. Mean 
aortic pressure was gradually increased from 50 mm Hg to 
80 mm Hg after electromechanical reanimation was ob- 
served. If fibrillation occurred, direct-current counter- 
shocks of 10 watt-seconds were applied. The heart was 
maintained in the vented total bypass tate for the initial 
30 minutes of reperfusion. After systemic blood Ca 2+ 
content was corrected to baseline values, 14 the dog was 
weaned off bypass and allowed to support he circulation 
for an additional 30 minutes in the working state. After 
postischemic hemodynamic and segmental function data 
were acquired at the end of 60 minutes of reperfusion, the 
heart was excised for the subsequent study of coronary 
artery endothelial function (description of in vitro study 
follows) by the organ bath technique. 3 
Determination of area at risk and infarct size. The 
interrupted left circumflex artery (LCx) segment was 
bridged with a polyethylene tube to reestablish perfusion 
continuity, and Unisperse blue dye (Ciba-Geigy, Inc., 
Newport, Del.) was perfused through the aortic root to 
stain the normally perfused region blue. The area at risk 
was demarcated by the lack of blue staining. The area of 
necrosis and infarct size were determined by triphenyltet- 
razolium chloride vital stain and gravimetric analysis as 
previously described. 3' 15 
Data acquisition and analysis. Hemodynamic data 
were acquired and processed by computer as detailed 
previously.3.16 Measurements were taken before coronary 
artery occlusion (control), after 90 minutes of occlusion, 
and after 60 minutes of reperfusion in the working state. 
Hemodynamic and cardiodynamic data were averaged 
and output was obtained from no fewer than 15 beats. The 
pressure-rate product, used as an index of myocardial 
oxygen demands, was calculated as the product of heart 
rate and peak left ventricular systolic pressure. Percent 
segmental shortening, segmental work, and the character- 
istics of segmental stiffness were determined as previously 
described. 3 
Plasma creatine kinase activity. Blood samples for 
measuring creatine kinase activity were withdrawn from 
the femoral artery at baseline, after 90 minutes of regional 
ischemia, at the end of i hour of cardioplegic arrest, at the 
end of beating-empty (30 minutes) reperfusion, a d at the 
end of 60 minutes of reperfusion. The plasma was ana- 
lyzed spectrophotometrically for creatine kinase activity 
(CK-10 kit; Sigma Diagnostic, St. Louis, Mo.) and protein 
concentration (Sigma Diagnostic). Creatine kinase activ- 
ity was expressed as international units per microgram of 
protein. 
Cardiac myeloperoxidase activity. Tissue samples weigh- 
ing approximately 0.4 gm were taken from the nonisch- 
emic zone and from the nonnecrotic and necrotic areas of 
the ischemic zone for spectrophotometric analysis of 
myeloperoxidase activity as an assessment of neutrophil 
accumulation i myocardium as described previously. 1 
In vitro coronary artery ring studies. Both the isch- 
emic-reperfused LAD and the nonischemic LCx were 
carefully dissected from the heart after the xperiment, 
cut into four rings of approximately 2 mm in length, 
connected to isometric force transducers (model TR; 
Radnoti 001, Monrovia, Calif.), and placed in organ 
chambers filled with 20 ml of 37°C Krebs-Henseleit 
solution with the following composition (in millimoles per 
liter): 118 NaC1, 4.7 KC1, 1.2 KHsPO4, 1.2 MgSO4, 2.5 
CaC12, 12.5 NaHCO3, and 10 glucose. Changes in isomet- 
ric force were digitized at 3 Hz with use of an analog-to- 
digital converter and an IBM-PC AT computer (IBM 
Corp., Armonk, N.Y.). Isometric force data were analyzed 
with use of a videographics program developed in our 
laboratory. 17After 60 minutes of equilibration, the rings 
were placed at the optimal point of their length-tension 
relationship with the use of potassium chloride 30 
mmol/L. After indomethacin 10 t~mol/L was used to 
prevent vascular esponses to endogenous prostacyclin, 
the optimal dose of U46619 was determined. Cumulative 
concentration-response curves to acetylcholine, a musca- 
rinic receptor-mediated endothelium-dependent stimula- 
tor of NO; the calcium ionophore A23187, a receptor- 
nonmediated endothelium-dependent stimulator of NO; 
and acidified (pH 2.0) sodium nitrite, an endothelium- 
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independent smooth muscle relaxing agent, were sequen- 
tially performed. Drug concentrations are expressed as 
the final concentration in the organ chamber. 
In addition, the heart was excised from six normal dogs 
and ring studies were done to obtain control data. 
Statistical analysis. Dogs were not included in the final 
analysis if (1) the cardioplegic solution was not within 
specified delivery pressure, pH, potassium concentration, 
or osmolarity, (2) ventricular fibrillation was unconverted 
after two direct-current shocks, or (3) the protocol was not 
satisfactorily completed. 
All data were analyzed with the Statistical Analysis 
System program (PC-SAS; SAS Institute, Cary, N.C.). 
Time-related ifferences and group-time interactions 
were analyzed by two-way analysis of variance for re- 
peated measures adjusted for baseline values. Infarct size 
and myeloperoxidase data were compared among the 
three groups by one-way analysis of variance. Responses 
to vasodilators in rings contracted with U46619 are ex- 
pressed as percent changes of tension from the precon- 
tracted levels, and those data are compared among the 
four groups at each concentration byone-way analysis of 
variance. ECso, the dose of the drug required to effect 
relaxation to 50% of maximum precontracted levels, 
was calculated and expressed as the negative log of the 
drug concentration. Holms' sequentially rejective meth- 
od a8 was used to reduce the chance of type 1 errors in 
multiple comparisons at a probability level of 0.05. All 
data are pre,;ented as means plus or minus the standard 
error of the mean. 
Results 
One dog in the BCP group had heartworms and 
was excluded. In one dog in the L-Arg group, the 
cardioplegic solution was not delivered within spec- 
ified deliveJ~ pressures and the dog was excluded. 
Twenty-three dogs (BCP = 10; L-Arg = 8; L-NA = 
5) were entered into the final data analysis of infarct 
size and regional function. 
Blood gas data obtained before bypass and after 
stabilization on bypass were not significantly differ- 
ent among the groups. 
Hemodynamics. In the standard BCP group, di- 
rect-current: countershock was required to convert 
ventricular fibrillation in four dogs during ischemia. 
In the L-Arg group, only two dogs required cardio- 
version during ischemia, and in the L-NA group, two 
dogs required cardioversion during ischemia. There 
were no group differences in the number of cardio- 
versions required during the early period of reper- 
fusion (BCP = 1, L-Arg = 1, L-NA = 1). 
Hemodyrtamic data for the three groups at base- 
line and during ischemia and reperfusion are sum- 
marized in Table I. There was a slight but significant 
difference in baseline mean arterial pressure be- 
tween the BCP and L-NA groups. During coronary 
occlusion, heart rate was significantly increased and 
Table II. Blood cardioplegia delivery volume in 
milliliters 
Warm Cold 20-Minute 40-Minute 
Group infusion infusion infusion infusion Terminal 
BCP 471_+64422_+37" 224_+27" 205_+22 348_+23" 
L-Arg 600--+78449--+44" 264_+15" 267_+21 416+17"  
L-NA 400_+36276- -12"7176_+12"?  169_+177307_+44"? 
Values are given as mean plus or minus the standard error ofthe estimate. 
*/)<0.05 versus previous period. 
?p < 0.05 versus L-Arg group. 
mean arterial pressure decreased significantly for all 
groups compared with the baseline value. Pressure 
rate product increased significantly in both the 
L-Arg and L-NA groups but decreased in the BCP 
group compared with the previous period. There 
were no group differences in any of the parameters 
during ischemia. During reperfusion, heart rate 
remained elevated in all groups and there was a 
significant difference between the BCP and L-NA 
groups. Mean arterial pressure did not change com- 
pared with the ischemic period. Pressure rate prod- 
uct during reperfusion increased significantly from 
ischemia for all groups, but with no group differ- 
ences. 
Myocardial temperature and elivery of blood 
cardioplegia. Myocardial temperatures were mea- 
sured in the anterior (ischemic) and posterior 
(nonischemic) walls of the left ventricle after each 
infusion of blood cardioplegic solution. Myocardial 
temperature was significantly higher in the ischemic 
zone than in the nonischemic zone during the cold 
induction phase when distribution of cardioplegic 
solution was impaired by the ligature. After release 
of the ligature before the 20-minute infusion, tem- 
perature in the ischemic zone was still significantly 
higher than that in the nonischemic zone by an 
average of 8 ° C, but there were no group differences. 
In addition there was a gradient between the nonis- 
chemic and previously ischemic zone after the ter- 
minal cardioplegia delivery. These persistent tem- 
perature gradients suggest an impairment of 
microvascular perfusion because no obvious epicar- 
dial coronary constriction was evident at the site of 
occlusion. 
The volume of blood cardioplegic solution deliv- 
ered during the cold phase of induction and during 
the intermittent infusions was significantly less than 
the initial warm induction volume (Table II). The 
volume of cold cardioplegic solution was particularly 
diminished in the L-NA group. Delivery volume 
increased significantly during the longer, normo- 
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Table III. Segmental length data for ischemic 
segment 
90 Minutes 
Baseline of ischemia Reperfusion 
EDL (mm) 
BCP 15.3 _+ 0.7 18.1 + 0.8* 15.7 _+ 0.8* 
L-Arg 16.1 +-- 0.7 19.0 Z 0.4* 16.7 + 0.9* 
L-NA 19.9 +- 0.7? 21.9 + 0.5"~ 18.0 -+ 1.1" 
ESL (mm) 
BCP 12.8 + 0.8 19.3 _+ 0.8* 15.5 _+ 0.8* 
L-Arg 13.3 _+ 0.6 20.4 _+ 0.5* 15.9 _+ 0.9* 
L-NA 17.1 _+ 0.9~ 22.6 +_ 0.5*? 18.1 _+ 1.1" 
Values are given as means plus or minusthe standard error ofthe estimate. 
EDL, End-diastolic length;ESL, end-systolic length. 
*p < 0.05 versus previous period. 
to< 0.05 versus other two groups. 
thermic terminal infusion relative to the 40-minute 
intermittent dose. There were no significant group 
differences in blood cardioplegia composition. 
Segmental systolic and diastolic function. At 
baseline and ischemia, end-diastolic and end-systolic 
segment lengths in the L-NA group were greater 
than those in the other two groups possibly because 
of placement of the ultrasonic transducers farther 
apart (Table III). Ischemia caused paradoxic systolic 
expansion so that end-systolic length exceeded end- 
diastolic length in all groups. Both the magnitude of 
systolic shortening and segmental work showed se- 
vere dyskinesis. Although dysfunction assessed by 
systolic shortening was not as severe in the L-NA 
group as in the other groups, segment work was 
equally depressed in all groups. During reperfusion, 
a significant decrease in segmental shortening and 
segmental work persisted in all groups, but the 
L-Arg group showed a significantly greater estora- 
tion of segment function compared with the other 
groups (Fig. 1). 
The/3-coefficient (modulus of diastolic segmental 
stiffness) of the exponential end-diastolic pressure- 
segment length relation is summarized in Fig. 2. 
LAD occlusion slightly increased the segmental 
stiffness above the respective baseline values in all 
groups; segmental stiffness in the L-NA group was 
significantly greater than that in the other two 
groups. During reperfusion, segmental stiffness was 
significantly less in the L-Arg group than in the BCP 
and L-NA groups, whereas stiffness in the L-NA 
group was significantly greater than that in the other 
two groups. Therefore both systolic and diastolic 
postischemic functions were improved by L-arginine 
treatment. 
Area at risk and infarct size. The mass of the left 
ventricle and area at risk were similar among the 
BCP, L-Arg, and L-NA groups. The area placed at 
risk by coronary occlusion expressed as a percentage 
of the left ventricular mass was comparable among 
all groups (Fig. 3). When necrosis was expressed as 
a percentage of left ventricular mass, there was a 
strong tendency (p = 0.08) for the L-Arg group to 
have a smaller infarct relative to the BCP group. In 
contrast, infarct size was significantly (p < 0.05) 
increased in the L-NA group compared with that in 
the BCP and L-Arg groups. 
The area of necrosis, expressed as a percentage of
the area at risk, shown in Fig. 3, was 30.4% less (p < 
0.05) in the hearts protected with L-arginine com- 
pared with that in the BCP group. In contrast, L-NA 
treatment significantly (p < 0.05) increased infarct 
size relative to that in the BCP group and that in the 
L-Arg group. Therefore Loarginine supplementation 
reduced infarct size by the L-arginine-NO pathway 
and blockade of this pathway not only reversed this 
effect, but also exacerbated infarct size. 
Plasma creatine kinase activity. There was no 
significant difference in plasma creatine kinase ac- 
tivity at baseline among the three groups (Table IV). 
All three groups showed a similar and significant 
increase in plasma creatine kinase activity during 
LAD occlusion but no further increase during blood 
cardioplegia delivery. After 60 minutes of reperfu- 
sion, all three groups showed increased plasma 
creatine kinase activity, which was significantly 
greater in the L-NA group than in the other two 
groups, consistent with the larger infarct size in that 
group. There was a tendency (p = 0.12) for the 
e-Arg group to have a lower creatine kinase activity 
compared with that of the BCP group. 
Cardiac myeloperoxidase activity. To validate 
the correlation between myeloperoxidase activity 
and neutrophil population, myeloperoxidase activity 
was assessed in a range (4.5 × 107 to 8.0 × 103 
cells/ml) of neutrophils. The correlation coefficient 
was 0.962 for the following relationship: log PMN = 
4.278 (MPO) + 33.13, where PMN is the number of 
neutrophils per milliliter and MPO is the myeloper- 
oxidase activity of the test PMN solution in units per 
milliliter. Therefore myeloperoxidase activity was 
highly correlated with the numbers of neutrophils in 
the test sample. In addition, the presence of the red 
triphenyltetrazolium chloride precipitate on viable 
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tissue did not interfere with the myeloperoxidase 
assay. 
Cardiac myeloperoxidase activities (expressed in 
units per gram tissue) in tissue samples from nonis- 
chemic, ischemic but nonnecrotic (triphenyltetrazo- 
lium chloride positive), and necrotic (triphenyltetra- 
zolium chloride negative) areas of myocardium are 
shown in Fig. 4. Myeloperoxidase activity in the 
nonischemic zone was low and comparable among 
the BCP, L-Arg, and L-NA groups. Myeloperoxidase 
activity in the ischemic nonnecrotic zone increased 
significantly higher than the values in the nonisch- 
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Fig. 3. Mass of area at risk versus mass of left ventricle as 
percentage (Ar/LV, top panel), mass of area of necrosis 
versus mass of left ventricle as percentage (An/LV, middle 
panel), and area of necrosis as percent of area at risk 
(An/Ar, bottom panel). Although area placed at risk was 
comparable among groups, area of necrosis/area at risk 
ratio was significantly reduced in L-Arg group and signif- 
icantly augmented in L-NA group. *p < 0.05 versus BCP 
and L-NA groups; **p < 0.05 versus BCP and L-Arg 
groups. Bars represent mean -+ standard error; circles 
represent individual values for each group. 
emic zone in the three groups. However, in hearts 
treated with L-arginine, myeloperoxidase activity 
was significantly (p < 0.05) reduced by 65.2% of that 
in the BCP group, whereas blockade of NO synthase 
activity with L-NA increased myeloperoxidase activ- 
ity. Therefore L-arginine prevented neutrophil accu- 
mulation in the nonnecrotic myocardium. However, 
in the necrotic zone, myeloperoxidase activity in the 
three groups was less than that in the ischemic 
nonnecrotic zone with no difference among the 
three groups and no difference from that in the 
nonischemic zone. 
In vitro coronary ring data. Our preliminary 
experiments showed that a 1 mmol/L concentration 
of L-NA was sufficient to block acetylcholine-stimu- 
lated, NO-induced relaxation. However, preliminary 
studies also showed that the antagonist effects of 
L-NA in normal coronary rings persist despite up to 
3 hours of continuous washout (data not shown), 
which is manifested as a 70% decrease in the 
maximal extent of relaxation, a dramatic right shift 
in the dose-response curve, and an increase in the 
EC50. Therefore L-NA infused in the experimental 
L-NA group would have influenced the ring analysis 
and created a drug-induced rather than injury- 
induced depression of relaxation responses. There- 
fore we excluded the L-NA group from in vitro 
coronary ring data analysis. The optimal passive 
length determined from length-tension responses to 
potassium chloride in the LAD was comparable 
among all groups. 
Enflothelium-flependent relaxations. Fig. 5 shows 
vasodilator responses to acetylcholine (upper panel) 
in the LAD and LCx rings, expressed as a percent- 
age of U46619-induced precontraction. Although 
acetylcholine caused concentration-dependent r - 
laxation responses in all three groups, differences in 
the magnitude of relaxation were observed among 
groups. There were no differences in the responses 
between LAD and LCx arteries in the control group. 
The concentration response curves in LAD rings 
exposed to both occlusion and cardioplegic schemia 
from the BCP and L-Arg groups were markedly 
shifted to the right compared with the curve from 
the control group, with a reduction in the maximum 
relaxation compared with that in the control group. 
However, the responses in the L-Arg group were 
significantly (p < 0.05) higher than those in the BCP 
group at the third to the sixth concentrations of
acetylcholine (0.085 to 1.685 ~mol/L). ECs0 
(-log[mol]), the dose of the drug required to effect 
relaxation to 50% of precontracted levels, also in- 
creased in the BCP (6.75 _+ 0.04) and L-Arg (6.93 -+ 
0.03) groups compared with those in the control 
group (7.52 _+ 0.07), but the increase in ECs0 in the 
L-Arg treatment group was significantly (p < 0.05) 
less compared with that in the BCP group (Fig. 6). 
The concentration response curves to acetylcholine 
in the LCx rings exposed to cardioplegic arrest only 
from the BCP and L-Arg groups were also markedly 
shifted to the right relative to those from the control 
group; the maximum relaxation was significantly 
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Table IV. Plasma creatine kinase activity (international units per milligram protein) during the time course of 
the experiment 
Blood Reperfusion Reperfusion 
Group Preischemia Ischemia cardioplegia (BE) (B W) 
BCP 0.79 + 0.18 6.64 +_ 0.83* 9.17 - 0.70 15.64 _+ 1.26" 20.71 _+ 1.73" 
L-Arg 0.75 + 0.13 7.21 +_ 1.17" 7.98 - 1,06 13.48 _+ 1.73" 17.62 + 3.36* 
L-NA 0.51 - 0.04 7.50 -+ 0.36* 7.47 - 0,64 18.25 -+ 4.53* 24.04 _+ 7.84"t 
BE, Beating empty; BW, beating working. 
*p < 0.05 versus previous period. 
tp < 0.05 versus the other two groups. 
reduced compared with that in the control group. In 
contrast o the ischemic-reperfused LAD, there 
were no differences in the acetylcholine r sponse 
curves between the L-Arg and BCP groups (Fig. 5) 
in the LCx rings exposed to cardioplegia-induced 
ischemia. Although the ECs0 in the BCP and L-Arg 
groups was significantly increased over that of the 
control group, the response was significantly ess in 
the L-Arg group (Fig. 6). 
The endothelium-dependent nonreceptor-medi- 
ated vasodilator A23187 also caused concentration- 
dependent relaxation in all three groups (Fig. 5). 
There were some minor differences in relaxation 
responses between groups; however, overall the
three groups were comparable and maximal relax- 
ations were complete (->100% of precontracted 
tension) although maximal relaxation was less in the 
BCP group than in the control or L-Arg groups. A 
similar pattern in relaxation response to A23187 was 
observed in the nonischemic LCx rings. ECs0 in the 
LAD ring was slightly smaller in the control group 
(7.72 __ 0.06) compared with that in the BCP 
(7.87 4- 0.04) and L-Arg (7.86 4- 0.03) groups; 
similarly, EC50 inthe LCx ring was slightly smaller in 
the control (7.80 _ 0.04) and BCP (7.94 4. 0.06) 
groups compared with that in the L-Arg group 
(7.90 4. 0.03). These data suggest that endothelium- 
dependent injury in this model is confined primarily 
to receptor-mediated processes, whereas nonrecep- 
tot-mediated relaxation responses remained largely 
intact. 
Endothelium-independent smooth-muscle relax- 
ations. Acidified sodium nitrite was used to induce 
endothelium-independent r laxation of vascular 
smooth muscle (Fig. 6). In the LAD rings, there 
were some depressed relaxation responses in the 
BCP and L-Arg groups relative to control group 
rings and the ECs0 values were significantly smaller, 
indicating a smaller degree of smooth muscle dys- 
function. However, maximal relaxations were com- 
parable among all groups. In the LCx, there were no 
significant differences among groups. These data 
indicate that L-arginine treatment protects the cor- 
onary receptor-mediated endothelial function from 
ischemia nd repeffusion damage, whereas neither 
endothelium-dependent nonreceptor-mediated va- 
sodilation or smooth muscle function was adversely 
affected. These data also suggest that superimposed 
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Fig. 5. Vasodilator responses in LAD and LCx vascular rings to acetylcholine, the receptor-dependent, 
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NO-stimulator calcium ionophore A23187 (middle panel); and smooth muscle relaxing NO donor agent 
acidified NaNO2 (bottom panel). Relaxation responses are expressed as percentage ofU46619-induced 
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coronary artery occlusion-induced ischemia and 
global cardioplegia-induced ischemia in the LAD 
produce more severe injury than cardioplegic arrest 
alone in the LCx. 
Discussion 
The present study tested the hypothesis that the 
physiologic precursor to NO, L-arginine, in blood 
cardioplegic solution and as intravenous infusate 
during reperfusion would reduce postischemic n- 
jury by a NO-related mechanism. We found that 
L-arginine used as an adjunctive agent attenuated 
infarct size by 30.4% compared with an unsupple- 
mented blood cardioplegic solution, preserved post- 
ischemic systolic and diastolic function in the area at 
risk, and reduced neutrophil accumulation i the 
ischemic-reperfused myocardium. This cardiopro- 
tective effect of L-arginine was also accompanied by
greater preservation of coronary vascular endothe- 
lial function related to stimulated production of NO. 
Our observations suggest hat reduction of acute 
myocardial infarct size and avoidance of segmental 
systolic and diastolic dysfunction may be attributed 
in part to inhibition of neutrophil activities including 
accumulation possibly by direct inhibition of neutro- 
phil adherence tocoronary endothelium, superoxide 
production by activated neutrophils, 19 and attenua- 
tion of neutrophil-dependent endothelial cell dam- 
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age.~, 20 The: observed cardioprotection most likely 
involved NO-related mechanisms because the NO- 
synthase blocker L-NA reversed the beneficial effect 
of L-arginine completely. Therefore supplementa- 
tion of blood cardioplegia and reperfusion reduced 
postischemic njury by mechanisms involving the 
L-arginine-NO pathway. This tudy adds to the 
growing number of studies that ascribe a beneficial 
role to NO in reducing the pathologic manifesta- 
tions of ischemia-reperfusion injury. 3' 21, 22 
Previous studies have demonstrated that both 
regional and global myocardial ischemia nd reper- 
fusion impair coronary vascular endothelial func- 
tion, characterized asreduced vasodilator responses 
to endothelium-dependent stimulation of nitric ox- 
ide. 1-6 In the present study, the ischemic-reperfused 
LAD sustained significantly greater endothelial 
damage than did the LCx, which underwent only 
cardioplegic arrest and repeffusion. This is consis- 
tent with the concept hat normothermic ischemia 
sets the stage for injury, whereas endothelial injury 
is expressed primarily during reperfusion. 2' 3, 23, 24 
The data also suggest that otherwise normal coro- 
nary arteries tolerate 1 hour of cardioplegic arrest 
well. Endothelial dysfunction in the LAD of the 
untreated BCP group was reversed by L-arginine, 
consistent with the dose-dependent reversibility 
shown by others 25' 26 and dose-dependent i racel- 
lular transport of L-arginine. 26 Results of the present 
study are consistent with the reversibility of ischemi- 
cally impaired endothelial dysfunction by supple- 
mental L-arginine. 3'21 These findings suggest that 
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endothelial dysfunction can be attenuated with myo- 
protective strategies that preserve the coronary en- 
dothelium at the time of cardioplegic infusion or 
blood reperfusion. Although previous tudies from 
our laboratory have shown that NO-donor agents 
are cardioprotective against global postischemic 
dysfunction, 6 more studies need to be done with 
models of acute coronary artery occlusion that sim- 
ulate surgical revascularization of evolving infarc- 
tion to determine optimal doses and applications of 
L-arginine, as well as the mechanisms involved in 
endothelial preservation. 
In the present study we found that neutrophil 
accumulation i the nonischemic myocardium (as- 
sessed by myeloperoxidase activity) was reduced by 
65.2% in dogs treated with L-arginine. However, 
there were no differences in myeloperoxidase activ- 
ity in the necrotic zone among the three groups. 
Previous studies by Chatelain and associates, 27 En- 
gler and Covell, 2s and Dreyer and associates 29have 
shown that reperfusion markedly enhances the infil-
tration of neutrophils into the ischemic-reperfused 
myocardium. One mechanism of the cardioprotec- 
tive and endothelial protective eff cts of L-arginine 
may be related to the antineutrophil properties of 
NO.a, ao, 30,31 The present study suggests that L- 
arginine treatment may be an effective therapy 
directed against neutrophil activity in surgical revas- 
cularization of acute myocardial infarction. The 
observation that myeloperoxidase activity was not 
increased in the necrotic region of the BCP and 
L-NA groups is in contrast to results of our previous 
studies in which L-arginine and NO-donor agent 
SPM-5185 reduced myeloperoxidase activity in the 
necrotic zone. a' 3 This may suggest hat neutrophil 
accumulation is not a mechanism associated with 
necrosis or that necrosis occurred before reperfu- 
sion-induced neutrophil accumulation i the surgi- 
cal model. Further studies are needed to resolve this 
issue. 
Repcrfusion of total coronary occlusion is accom- 
panied by severe systolic and diastolic contractile 
dysfunction 3, 15 even in the absence of infarc- 
tion. 3a-34 Surgical reperfusion with use of a period of 
blood cardioplegia-induced arrest allows partial res- 
toration of regional postischemic dysfunction, but 
significant hypokinesis persistsY' 36 In the present 
study, we found that ischemic-reperfused segments 
treated with blood cardioplegic solution enhanced 
with L-arginine demonstrated significantly better 
postischemic systolic and diastolic function than 
hearts treated with unenhanced blood cardioplegic 
solution. This functional preservation was not only 
reversed but exacerbated by the NO synthase antag- 
onist L-NA. These data confirm involvement of the 
L-arginine-NO synthase pathway and are consistent 
with previous reports from this laboratory in which 
L-arginine produced temporary recovery of regional 
postischemic function after nonsurgical reperfusion 3 
and NO donor agents increased regional or global 
functional recovery after nonsurgical and surgical 
reperfusion. 1'6'37 In the nonsurgical models, 1'3 
preservation of postischemic ontractile perfor- 
mance may be associated with a concomitant reduc- 
tion in infarct size, as in the present study. However, 
because even noninfarcted myocardium exhibits 
postischemic dysfunction (stunning), 33 protective 
mechanisms with L-arginine treatment may also 
involve preservation of the contractile apparatus or 
myocyte calcium kinetics. 38' 39 Further studies would 
be required to elucidate the exact mechanism or 
mechanisms responsible for preservation of post- 
ischemic systolic and diastolic function with L-argi- 
nine treatment. However, inhibition of neutrophils 
and neutrophil-mediated damage to the contractile 
apparatus may be implicated from the present study 
and those of others, a°' 41 
In summary, L-arginine used as an adjunct to 
blood cardioplegia nd as intravenous therapy re- 
duced infarct size and restored partial postischemic 
systolic and diastolic function in the ischemic-reper- 
fused segment. Blockade of these beneficial effects 
by the NO synthase inhibitor suggests that this 
cardioprotection was expressed through the L-argi- 
nine-NO pathway and most likely involved inhibi- 
tion of neutrophil accumulation within the area at 
risk and preservation of the coronary vascular en- 
dothelium. The results of this study suggest that (l) 
the endogenous L-arginine-NO pathway acts as an 
inherent cardioprotective mechanism unmasked by 
L-NA and (2) L-arginine may act by recruiting 
endogenous NO, presumably from the vascular en- 
dothelium. The results are in contrast with data 
from Matheis and associates 42that suggest that NO 
is a mediator of deleterious processes in models of 
hypoxia-reoxygenation njury, possibly via conver- 
sion to peroxynitrite and hydroxyl radicals. 43' 44 The 
present study supports the use of adjunctive L- 
arginine during cardiac operations in addition to 
exogenous donors of NO. As suggested by the study 
of Cohen and colleagues, a5the L-arginine-NO path- 
way may be recruited by pretreatment with precur- 
sor L-arginine before cardiac operation or by oral 
doses before operation. 
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